Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Incorporated on 22nd July 1980, AVI BioPharma is a biopharmaceutical company developing therapeutic products
based on two distinct core technologies, its NeuGene antisense technology and its Avicine cancer vaccine. Its principal
products will target life-threatening diseases, with initial applications in colorectal cancer, pancreatic cancer,
cardiovascular disease, polycystic kidney disease and drug metabolism. According to AVI, its preclinical and clinical
studies indicate that its two core technologies may produce drugs that offer more effective treatment options and
produce significantly fewer side effects than currently approved products.